Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).

Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). Am Heart J. 2002 Dec; 144(6):995-1002.

View in: PubMed

subject areas

Acetates
Acute Disease
Aged
Anticoagulants
Coronary Disease
Data Interpretation, Statistical
Drug Therapy, Combination
Female
Heparin
Heparin, Low-Molecular-Weight
Humans
Male
Middle Aged
Myocardial Revascularization
Platelet Aggregation Inhibitors
Platelet Glycoprotein GPIIb-IIIa Complex
Randomized Controlled Trials as Topic
Survival Analysis
Tyrosine

authors with profiles

Robert Harrington